EN | TR
E-ISSN: 3061-9947
Clinical Importance of the Hemoglobin, Albumin, Lymphocyte, Platelet Score in Metastatic Pancreatic Cancer
PDF
Cite
Share
Request
Original Article
VOLUME: 56 ISSUE: 3
P: 250-258
2023

Clinical Importance of the Hemoglobin, Albumin, Lymphocyte, Platelet Score in Metastatic Pancreatic Cancer

Acta Haematol Oncol Turc 2023;56(3):250-258
DOI: 10.5505/aot.2023.26779
Onur Yazdan Balçık 1
Ali Aytaç 2
Ferhat Ekinci 3
Yusuf İlhan 4
Bilgin Demir 5
Gökhan Karakaya 6
Atike Pınar Erdoğan 7
1. Mardin Training And Research Hospital, Deparment Of Medical Oncology, Mardin, Turkey.
2. Aydın Adnan Menderes University Application And Research Hospital, Deparment Of Medical Oncology, Aydın, Turkey
3. Şırnak State Hospital, Deparment Of Medical Oncology, Şırnak, Turkey
4. Antalya Training And Research Hospital, Antalya, Turkey
5. Aydin Ataturk State Hospital, Deparment Of Medical Oncology, Aydın, Turkey
6. Akdeniz Sağlık Vakfı Yaşam Hospital, Deparment Of Medical Oncology, Antalya, Turkey
7. Manisa Celal Bayar University, Hafsa Sultan Hospital, Deparment Of Medical Oncology, Manisa, Turkey
8.
No information available.
No information available
Received Date: 2023-07-25T01:16:15
Accepted Date: 2023-12-04T07:27:18
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Pancreatic adenocarcinoma is one of the deadliest cancers. Effective, simple and practical methods that can be used in daily life are still lacking to predict the prognosis of patients with advanced pancreatic cancer and a promising biomarker is needed to predict prognosis. Our study's objective was to demonstrate the correlation between the HALP score and prognosis in patients with metastatic pancreatic cancer.

METHODS

Patients diagnosed with metastatic pancreatic cancer from 4 centers in Turkey between 2016 and 2022 were included. Demographic data, hemogram parameters, biochemistry values, as well as the treatments received were recorded. Survivals were also recorded

RESULTS

There were 280 patients in our study. The median PFS was 7.53 months, while the median OS was 11.53 months for the whole population. Median PFS was 7.1 months for the HALP-Low group and 14.8 months for the HALP-High group. The HALP-Low group exhibited a significantly shorter median progression-free survival (PFS) compared to the HALP-High group, with a statistically significant difference between the two groups (p<0.001). Median OS was 10.57 months for the HALP-Low group and 18 months for the HALP-High group. The HALP-Low group demonstrated a significantly shorter median overall survival (OS) compared to the HALP-High group, with a statistically significant difference between the two groups (p<0.001)

DISCUSSION AND CONCLUSION

In conclusion, the HALP score is an inexpensive, practical, literature-contributing marker and, if validated by prospective studies, can be used in routine clinical practice to predict the prognosis of patients with metastatic pancreatic cancer.